en · de · es · pt
melanotan-2-notes.peptides8425.com › Info › Melanotan-2 Structure And Receptor Pharmacology — Questions and Answers

Melanotan-2 Structure And Receptor Pharmacology — Questions and Answers

By Editorial Desk · published 2025-11-09 · last reviewed 2025-11-26 · Info

Everything below concerns eumelanin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2025-11-26. Numbers and descriptions here follow the published literature rather than marketing material.

Melanotan-2 Structure and Receptor Pharmacology

Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.

Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.

No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.

Storage, Stability, and Analysis

Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.

Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.

Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Free base; salt forms add to total mass
Molecular massAbout 1024 daltonsCalculated for the free base
Structural classCyclic heptapeptideContains D-phenylalanine and norleucine
Parent hormoneAlpha-melanocyte-stimulating hormoneEndogenous tridecapeptide of 13 residues
Receptor profileNon-selective melanocortin agonistInteracts with MC1R, MC3R, MC4R and MC5R

Background and Receptor Mechanism

Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.

Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.

Related pages on this site

Regulatory Status and Literature Discussion

Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.

Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.

Reference notes

244Cm(12C,xn)256−xNo (x=4,5) This reaction was studied in 1958 by scientists at the LBNL using a 95% 244Cm curium target. They were able to measure 7.43 MeV decays from250Fm, associated with a 3 s 254No parent activity, resulting from the reaction (246Cm,4n). The 3 s activity was later reassigned to252No, resulting from reaction (244Cm,4n). It could however not be proved that it was not due to the contaminant 250mFm, unknown at the time. Later work in 1959 produced 8.3 MeV alpha particles with a half-life of 3 s and a 30% SF branch. This was initially assigned to 254No and later reassigned to 252No, resulting from reaction with the 244Cm component in the target. The reaction was restudied in 1967 at the LBNL and a new activity assigned to 251No was measured.

=== Land reform === Segni's appointment seemed to halt Gullo's agrarian reform drive: between September 1946 and December 1947 issued two decrees that allowed landowners to reclaim unimproved lands. This secured the support of southern elites for the Christian Democrat party, enabling it to win the 18 April 1948 general elections. It increased the tension between the two factions and rekindled laborer occupation of uncultivated land. The Massacre of Melissa, took place in Calabria: on 24 October 1949, some 14,000 peasants from Catanzaro and Cosenza, accompanied by women, children and work animals, occupied the large latifundia and began planting. A group of agrarian Calabrian CD parliamentarians went to Rome, protesting and asking Scelba to use force against the peasants. Scelba sent Mobile Units (mechanized riot police), to Calabria, which stopped at Melissa, in Crotone, finding a large number of protesters on the Fragalà estate, owned by Baron Luigi Berlingeri. The land was supposed to be assigned to the municipality, but the Berlingeri family had usurped it. The peasants claimed at least half of it, but the baron was willing to cede only a third. On 29 October 1949, police, after demanding the crowd of peasants to leave, fired at eye level, wounding 15 wounded and killing 3: Giovanni Zito, Francesco Nigro, and Angelina Mauro. This massacre, combined with that of Portella della Ginestra, in Sicily, which took place on 1 May 1947, provoked strikes and peasant demonstrations throughout Italy.

=== Australia === From 2023, Juniper was cited in multiple reports examining the regulation of telehealth-based weight-loss services in Australia. The Royal Australian College of General Practitioners (RACGP) and medical regulators raised concerns about prescribing models relying on asynchronous or questionnaire-based assessments for injectable weight-loss medications. The TGA assessed whether online advertising by Juniper (and its competitors) could indirectly promote prescription-only medicines in breach of federal law. Between 2022 and 2024 they requested the removal of thousands of unlawful advertisements. In response to updated guidance from the Medical Board of Australia (MBA) restricting "tick-and-flick" prescribing, Eucalyptus Health said that its platforms would comply with requirements for real-time clinical consultation and enhanced verification. In July 2023, the TGA opened an investigation into whether email communications sent by Juniper to people on its contact list about the availability of Ozempic constituted unlawful advertising. Through 2024, the TGA proposed the removal of GLP-1 medicines from pharmacy compounding exemptions due to concerns that telehealth prescribing models were inconsistent with exemptions intended for individual patient use. They warned that compounded GLP-1 products were not subject to the same safety, quality, or adverse-event reporting requirements as TGA-approved medicines. Juniper was one of the companies prescribing them.

Sources: en.wikipedia.org

Reference notes

=== Inlet types and flow rates === The choice of inlet type and injection technique depends on if the sample is in liquid, gas, adsorbed, or solid form, and on whether a solvent matrix is present that has to be vaporized. Dissolved samples can be introduced directly onto the column via a COC injector, if the conditions are well known; if a solvent matrix has to be vaporized and partially removed, a S/SL injector is used (most common injection technique); gaseous samples (e.g., air cylinders) are usually injected using a gas switching valve system; adsorbed samples (e.g., on adsorbent tubes) are introduced using either an external (on-line or off-line) desorption apparatus such as a purge-and-trap system, or are desorbed in the injector (SPME applications).

Russian Victory Day parades are organized annually in most cities, with the central military parade taking place in Moscow (just as during the Soviet times). Additionally, the recently introduced Immortal Regiment on 9 May sees millions of Russians carry the portraits of their relatives who fought in the war. Russia also retains other Soviet holidays, such as the Defender of the Fatherland Day (23 February), International Women's Day (8 March), and International Workers' Day.

Reticulocytes: Increased (normal range: 0.5–1.5% of the RBC listed above). The body to mass-produces red blood cells (reticulocytes being young erythrocytes) even as the spleen filters spherocytes out. This is known as reticulocytosis. Unconjugated bilirubin: Increased (normal range: 0.2–1.2 mg/dL). This is caused by heme released into the hepatosplenic circulation by macrophages that have phagocytosed erythrocytes. The unconjugated bilirubin is not soluble in water (blood), so it binds to albumin, and is processed in the liver. Haptoglobin (free): Decreased (normal range: 41–165 mg/dL). This is caused by hemoglobin binding to haptoglobin, thus making it no longer "free". Lactate dehydrogenase (LDH): Increased (normal range: 110–295 U/L in children). This is due to extravascular hemolysis. Peripheral blood smear: Directly shows spherocytes on microscope. Eosin-5-maleimide binding test: Positive (reduced mean fluorescence), as the test will demonstrate a reduced ability of the eosin-5-maleimide dye to bind to erythrocyte plasma membrane proteins. The process relies upon flow cytometry. Gold standard test that produces results at low cost within ~2 hours. In chronic cases, patients who have taken iron supplementation, have heterozygous hemochromatosis, or received numerous blood transfusions, iron overload may cause additional health issues. Measuring iron stores is sometimes considered part of the diagnostic approach to hereditary spherocytosis in older patients presenting with heart muscle damage of unknown etiology or liver disease without apparent cause.

Sources: en.wikipedia.org

Notes from published material

==== States reject distributors' settlement ==== In February 2020, 21 US states turned down an $18 billion (US), 18-year offer from McKesson Corporation, Cardinal Health Inc, and AmerisourceBergen Corp. that would have resolved litigation against the pharmaceutical companies over their distribution of the addictive painkillers. A letter from the attorneys general of Ohio, Florida and Connecticut (among others) said the settlement, as "currently structured," was not acceptable to the states. This particular offer was part of the proposed $50 billion (US) agreement to find a resolution to over 2,000 lawsuits from both local and state governments attempting to recoup billions of dollars they have spent combatting the crisis.

MS is not considered a hereditary disease, but over 200 genetic variants have been shown to increase its risk. The probability of developing MS is higher in relatives of an affected person, with a greater risk among those more closely related. An identical twin of an affected individual has a 30% chance of developing MS, 5% for a nonidentical twin, 2.5% for a sibling, and an even lower chance for a half-sibling. MS is also more common in some ethnic groups than others. Specific genes linked with MS include differences in the human leukocyte antigen (HLA) system—a group of genes on chromosome 6 that serves as the major histocompatibility complex (MHC). The MHC is involved in how antigens are presented and how abundant different types of T cells are. The MHC allele (genetic variant) HLA-DRB1*15:01 which is present in 30% of the U.S. and Northern European population, produces the strongest association with higher risk of MS. Other allelles related to MHC exhibit a protective effect. The contribution of HLA variants to MS susceptibility has been known since the 1980s, and it has also been implicated in the development of other autoimmune diseases. Genetic variants in autoimmune diseases are typically linked to T cells, but in MS (and lupus), many are linked to B cells too. In general, MS is associated more closely to autoimmune diseases than to other neurodegenerative diseases.

In the synthesis of DNA templated combinatorial libraries, the ability of the DNA double helix to direct region-specific chemical reactions is harnessed by Gartner et al. The DNA- linked reagents are kept in close proximity. This is equivalent to the virtual increase of local concentration that is nearly constant within a distance of 30 nucleotides. The proximity effect helps reactions to proceed. Two libraries are synthesized. A template library containing at one end one of the BBs and its code followed by two annealing regions for the codes of the BBs of the two reagent libraries. Each of the two reagent libraries contains a coding oligonucleotide linked with cleavable bonds to the reagent (BB) capable of forming a bond with the already linked BB taking advantage of the proximity effect. The synthesis is realized in two steps as shown in the figure. Each step has three operations: mixing, annealing, coupling-cleaving.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan-2 approved for medical use?

No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.

How does melanotan-2 differ from melanotan-1?

Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.

What is the connection to alpha-MSH?

Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.

How is the peptide usually stored?

The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.

Network